The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market From 2026 To 2030?

The market size for chronic inflammatory demyelinating polyneuropathy (cidp) has shown substantial expansion in recent years. It is anticipated to increase from $2.27 billion in 2025 to $2.46 billion in 2026, at a compound annual growth rate (CAGR) of 8.1%. The growth observed in the past can be ascribed to several factors, including heightened awareness of rare autoimmune neuropathies, broader access to ivig therapies, progress in electrodiagnostic testing, a rise in specialist neurology care, and more effective recognition of cidp subtypes.

The market for chronic inflammatory demyelinating polyneuropathy (cidp) is anticipated to undergo significant expansion over the coming years, with projections indicating a rise to $3.32 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.8%. This growth in the forecast period is fueled by the escalating development of targeted immunotherapies, a heightened emphasis on mitigating treatment side effects, the broadening reach of remote patient monitoring, increasing patient demand for therapies that offer sustained remission, and greater investments in rare disease research. Prominent trends observed during this forecast period include the expanding application of IVIG as a first-line therapy, the increasing adoption of personalized treatment regimens, enhanced integration of advanced diagnostic tools, the proliferation of home-based treatment models, and an intensified focus on long-term disease management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?

The future expansion of the chronic inflammatory demyelinating polyneuropathy (CIDP) market is expected to be propelled by rising healthcare expenditure. This increase in healthcare spending is driven by greater investments in medical infrastructure, a growing demand for advanced treatments, expanded insurance coverage, and government efforts to enhance healthcare accessibility. High healthcare expenditure facilitates improved access to sophisticated treatments, early diagnosis, and better management of CIDP, thereby enhancing patient outcomes and quality of life. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure saw a 5.6% increase in nominal terms from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth observed in 2022. Consequently, increasing healthcare expenditure is a key driver for the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market.

Which Segments Are Included In The Analysis Of The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?

The chronic inflammatory demyelinating polyneuropathy (cidp) market covered in this report is segmented –

1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments

2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administrations

3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis

4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics

5) By End User: Hospitals, Research Institutions, Homecare Settings

Subsegments:

1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy

2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids

3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis

4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy

5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies

What Trends Are Projected To Affect The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?

Major companies in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are focusing on innovations such as intravenous immunoglobulin (IVIG) therapy to improve treatment effectiveness, achieve better patient outcomes, and provide more precise and efficient immune modulation for managing CIDP. Intravenous immunoglobulin (IVIG) therapy is a medical treatment that involves administering concentrated antibodies from healthy donors to help regulate the immune system and decrease inflammation in autoimmune conditions. For instance, in January 2024, Takeda Pharmaceutical Company Limited, a biopharmaceutical company based in Japan, declared FDA approval for GAMMAGARD LIQUID as an intravenous immunoglobulin (IVIG) therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This authorization permits its application as an induction therapy, initiating with an initial dose followed by maintenance doses to aid long-term disease control and enhance neuromuscular function.

Which Key Industry Participants Are Active In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?

Major companies operating in the chronic inflammatory demyelinating polyneuropathy (cidp) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Hualan Biological Engineering Inc, argenx SE, Bio Products Laboratory Ltd., Kedrion S.p.A, Biotest AG, Hansa Biopharma AB, UCB SA, Teva Pharmaceutical Industries Ltd, Merck & Co Inc, Roche Holding AG, Biogen Inc, Momenta Pharmaceuticals, Teijin Pharma Limited, Sanquin Plasma Products BV, Fresenius Kabi AG, Immunovant Sciences GmbH, Akari Therapeutics Plc, GeNeuro Pharmaceuticals, MedDay Pharmaceuticals, HanAll Pharma

Read the full chronic inflammatory demyelinating polyneuropathy (cidp) market report here:

https://www.thebusinessresearchcompany.com/report/chronic-inflammatory-demyelinating-polyneuropathy-cidp-global-market-report

What Are The Leading Geographic Regions In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?

North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2025. The regions covered in the chronic inflammatory demyelinating polyneuropathy (cidp) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21144&type=smp

Browse Through More Reports Similar to the Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market 2026, By The Business Research Company

Hepatitis B Virus Hbv Global Market Report

https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Preventive Vaccines Global Market Report

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Viral Hepatitis Global Market Report

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model